CD34+ cells in peripheral blood of healthy human beings and allergic subjects: clue to acute and minimal persistent inflammation.
BACKGROUND
There is compelling evidence that hemopoietic precursor cells (HPC) play a crucial role in establishing cellular inflammation in allergic diseases. Increased levels of circulating CD34+ HPC committed to the myeloid lineage have been extensively reported in allergic rhinitis, asthma and eczema, whereas CD34+ cells have been identified within the cellular infiltrates of tissues, at peripheral sites of inflammation.


METHODS
We conducted a pilot study to evaluate CD34+ traffic in the peripheral blood of 22 consecutive patients (13 men and nine women; mean age 28.9 years), independently of treatment. The patients presented rhinitis, asthma, eczema, urticaria and adverse food reactions of suspected allergic origin. Allergic reactions were extrinsic in 18 patients and intrinsic in four. In 12 patients who underwent sublingual specific immunotherapy, CD34+ cells were quantified at enrollment (T0), one year later (T1) and two years later (T2). The severity of symptoms was graded on a five-point scale (0 = absence of symptoms and 4 = severe symptoms). Twenty healthy human subjects (10 men and 10 women; mean age 24.5 years) were evaluated as controls. To obtain information about the total amount of circulating HPC, independently of the lineage commitment (Lin+/-) and the degree of differentiation (CD34bright/dim), we used a modification of the Milan protocol of peripheral blood CD34+ cell estimation. The cells were analyzed using a BD FACScan or FACSCalibur and the results were expressed as the percentage of positive cells.


RESULTS
CD34+ cell traffic in the control group was very low since all values were < 0.10 (median value: 0.03 %). Values in the patient group were increased in both extrinsic and intrinsic forms with a median value of 0.25 % (interquartile range: 0.13- 0.33 %). The relationship between CD34+ traffic and the severity score was highly significant (Spearman's rho = 0.954; test of Ho: CD34; independent score: Pr > t = 0.000).


CONCLUSIONS
The data reported herein suggest that the method employed is effective in assessing acute allergic inflammation, as well as minimal persistent inflammation underlying an asymptomatic clinical condition. Evaluation of CD34bright/dim peripheral traffic, if confirmed by the outcomes of a multicenter study currently being planned together with traditional study of circulating IgE, could be a reliable non-invasive laboratory tool for monitoring allergic inflammation.
Mastrandrea
F
F
Allergy and Clinical Immunology Operative Unit, A.O.S.S. Annunziata, Taranto, Italy.
Coradduzza
G
G
De Vita
L
L
Minardi
A
A
Scarcia
G
G
Marcucci
F
F
Parmiani
S
S
D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D018952:Antigens, CD34 / Q000032:analysis*; D001249:Asthma / Q000097:blood; D001772:Blood Cell Count; D002454:Cell Differentiation; D002648:Child; D003888:Desensitization, Immunologic; D005260:Female; D005434:Flow Cytometry; D005512:Food Hypersensitivity / Q000097:blood; D006412:Hematopoietic Stem Cells; D006801:Humans; D006967:Hypersensitivity / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012189:Retrospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000097:blood; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood; D014581:Urticaria / Q000097:blood
D018926:Anti-Allergic Agents; D018952:Antigens, CD34